Sandbox Epi: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
===Prevalence=== | ===Prevalence=== | ||
* In the United States, the [age adjusted] prevalence of (insert disease name here) is _____ % in (insert year here). | * In the United States, the [age adjusted] prevalence of (insert disease name here) is _____ % in (insert year here).<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
===Incidence=== | ===Incidence=== | ||
* The delay-adjusted incidence of (insert disease name here) in (insert year here) was estimated to be _____ per 100,000 persons in the United States. | * The delay-adjusted incidence of (insert disease name here) in (insert year here) was estimated to be _____ per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
* In (insert year here), the age-adjusted incidence of (insert disease name here) was _____ per 100,000 persons in the United States. | * In (insert year here), the age-adjusted incidence of (insert disease name here) was _____ per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
===Age=== | ===Age=== | ||
* While the overall age adjusted incidence of (insert disease name here) in the United States between (insert year here) and (insert year here) is _____ per 100,000, the age-adjusted incidence of (insert disease state here) by age category is: | * While the overall age adjusted incidence of (insert disease name here) in the United States between (insert year here) and (insert year here) is _____ per 100,000, the age-adjusted incidence of (insert disease state here) by age category is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
** Under 65 years: _____ per 100,000 | ** Under 65 years: _____ per 100,000 | ||
** 65 and over: _____ per 100,000 | ** 65 and over: _____ per 100,000 | ||
| Line 17: | Line 17: | ||
===Gender=== | ===Gender=== | ||
* In the United States, the [age adjusted] prevalence of (insert disease state here) by gender in (insert year here) is: | * In the United States, the [age adjusted] prevalence of (insert disease state here) by gender in (insert year here) is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
** In females: _____ % | ** In females: _____ % | ||
** In males: _____ % | ** In males: _____ % | ||
* In the United States, the delay-adjusted incidence of (insert disease state here) by gender in (insert year here) is: | * In the United States, the delay-adjusted incidence of (insert disease state here) by gender in (insert year here) is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
** In females: _____ per 100,000 persons | ** In females: _____ per 100,000 persons | ||
** In males: _____ per 100,000 persons | ** In males: _____ per 100,000 persons | ||
* In the United States, the age-adjusted incidence of (insert disease state here) by gender on (insert year here) is: | * In the United States, the age-adjusted incidence of (insert disease state here) by gender on (insert year here) is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
** In females: _____ per 100,000 persons | ** In females: _____ per 100,000 persons | ||
** In males: _____ per 100,000 persons | ** In males: _____ per 100,000 persons | ||
| Line 35: | Line 35: | ||
===Race=== | ===Race=== | ||
* In the United States, the [age adjusted] prevalence of (insert disease state here) by race in (insert year here) is: | * In the United States, the [age adjusted] prevalence of (insert disease state here) by race in (insert year here) is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
** In all races: _____ % | ** In all races: _____ % | ||
** In white: _____ % | ** In white: _____ % | ||
| Line 42: | Line 42: | ||
** In Hispanic: _____ % | ** In Hispanic: _____ % | ||
* In the United States, the race that is most susceptible to developing this disease/condition, is the ____ race. | * In the United States, the race that is most susceptible to developing this disease/condition, is the ____ race.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
Shown below is an image depicting the incidence of (insert disease name here) by race in the United States between (insert year range here). | Shown below is an image depicting the incidence of (insert disease name here) by race in the United States between (insert year range here).<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
[Insert figure x.2 from the report] | [Insert figure x.2 from the report] | ||
| Line 50: | Line 50: | ||
===Percent Distribution of (insert disease name here) by Histology=== | ===Percent Distribution of (insert disease name here) by Histology=== | ||
* Among patients with histologically confirmed cases of (insert disease name here), the percent distribution of the types of the disease between 2004 and 2010 in the United States are: | * Among patients with histologically confirmed cases of (insert disease name here), the percent distribution of the types of the disease between 2004 and 2010 in the United States are:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
** Type X: _____ % | ** Type X: _____ % | ||
** Type Y: _____ % | ** Type Y: _____ % | ||
| Line 58: | Line 58: | ||
===5 Year Survival==== | ===5 Year Survival==== | ||
* Between (insert age here) and (insert age here), the 5 year relative survival of patients with (insert disease name here) was _____ %. | * Between (insert age here) and (insert age here), the 5 year relative survival of patients with (insert disease name here) was _____ %.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
* When stratified by age, the 5 year relative survival of patients with (insert disease name here) was ____ % and ____ % for patients <65 and ≥ 65 years of age respectively. | * When stratified by age, the 5 year relative survival of patients with (insert disease name here) was ____ % and ____ % for patients <65 and ≥ 65 years of age respectively.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
* The survival of patients with (insert disease name here) varies with the stage of the disease. Shown below is a table depicting the 5 year relative survival by the stage of (insert disease name here): | * The survival of patients with (insert disease name here) varies with the stage of the disease. Shown below is a table depicting the 5 year relative survival by the stage of (insert disease name here):<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
| Line 79: | Line 79: | ||
|} | |} | ||
Shown below is an image depicting 5 year conditional relative survival (probability of surviving in the next 5 years given the cohort has already survived 0, 1, 3 years) by stage at diagnosis according to SEER. | Shown below is an image depicting 5 year conditional relative survival (probability of surviving in the next 5 years given the cohort has already survived 0, 1, 3 years) by stage at diagnosis according to SEER.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
[Insert figure x.5 here] | [Insert figure x.5 here] | ||
Revision as of 13:25, 11 June 2014
Prevalence
- In the United States, the [age adjusted] prevalence of (insert disease name here) is _____ % in (insert year here).[1]
Incidence
- The delay-adjusted incidence of (insert disease name here) in (insert year here) was estimated to be _____ per 100,000 persons in the United States.[1]
- In (insert year here), the age-adjusted incidence of (insert disease name here) was _____ per 100,000 persons in the United States.[1]
Age
- While the overall age adjusted incidence of (insert disease name here) in the United States between (insert year here) and (insert year here) is _____ per 100,000, the age-adjusted incidence of (insert disease state here) by age category is:[1]
- Under 65 years: _____ per 100,000
- 65 and over: _____ per 100,000
Gender
- In the United States, the [age adjusted] prevalence of (insert disease state here) by gender in (insert year here) is:[1]
- In females: _____ %
- In males: _____ %
- In the United States, the delay-adjusted incidence of (insert disease state here) by gender in (insert year here) is:[1]
- In females: _____ per 100,000 persons
- In males: _____ per 100,000 persons
- In the United States, the age-adjusted incidence of (insert disease state here) by gender on (insert year here) is:[1]
- In females: _____ per 100,000 persons
- In males: _____ per 100,000 persons
Shown below is an image depicting the delay-adjusted incidence of (insert disease name here) by gender and race in the United States between (insert year range here).
[Insert figure x.1 from the report]
Race
- In the United States, the [age adjusted] prevalence of (insert disease state here) by race in (insert year here) is:[1]
- In all races: _____ %
- In white: _____ %
- In black: _____ %
- In Asian/pacific islander: _____ %
- In Hispanic: _____ %
- In the United States, the race that is most susceptible to developing this disease/condition, is the ____ race.[1]
Shown below is an image depicting the incidence of (insert disease name here) by race in the United States between (insert year range here).[1]
[Insert figure x.2 from the report]
Percent Distribution of (insert disease name here) by Histology
- Among patients with histologically confirmed cases of (insert disease name here), the percent distribution of the types of the disease between 2004 and 2010 in the United States are:[1]
- Type X: _____ %
- Type Y: _____ %
- Type Z: _____ %
5 Year Survival=
- Between (insert age here) and (insert age here), the 5 year relative survival of patients with (insert disease name here) was _____ %.[1]
- When stratified by age, the 5 year relative survival of patients with (insert disease name here) was ____ % and ____ % for patients <65 and ≥ 65 years of age respectively.[1]
- The survival of patients with (insert disease name here) varies with the stage of the disease. Shown below is a table depicting the 5 year relative survival by the stage of (insert disease name here):[1]
| Stage | 5 year relative survival (%), (Insert range of years here) |
| All stages | |
| Localized | |
| Regional | |
| Distant | |
| Unstaged |
Shown below is an image depicting 5 year conditional relative survival (probability of surviving in the next 5 years given the cohort has already survived 0, 1, 3 years) by stage at diagnosis according to SEER.[1]
[Insert figure x.5 here]
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.